Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer

Eralp Y., Keskin S., Akisik E. E., Akisik E., Igci A., Muslumanoglu M., ...Daha Fazla

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 36 Sayı: 3
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1097/coc.0b013e318243913f
  • Dergi Adı: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.215-223
  • Anahtar Kelimeler: breast cancer, mRNA, response to neoadjuvant chemotherapy, survivin, GSTP1, topoisomerase 2A, GLUTATHIONE-S-TRANSFERASE, SURGICAL ADJUVANT BREAST, ANTHRACYCLINE-BASED CHEMOTHERAPY, PROJECT PROTOCOL B-27, II-ALPHA, PREOPERATIVE CHEMOTHERAPY, ESOPHAGEAL CANCER, SYSTEMIC THERAPY, TAXOL RESISTANCE, DRUG-RESISTANCE
  • İstanbul Üniversitesi Adresli: Evet

Özet

Introduction: The primary aim of this study is to investigate the effect of change in the expression levels of survivin, glutathione-S-transferase P1 (GSTP1), and topoisomerase 2 alpha (TOP2A) on the response to antracyclin-based and taxane-based neoadjuvant chemotherapy.